Five Additional Leading Physicians to Join Cellectis Clinical Advisory Board
08 March 2017 - 8:30AM
Business Wire
New Board Members Include Hematology Experts
Catherine Bollard, Hervé Dombret, Ola Landgren, Marcela Maus &
Dietger Niederweiser
Regulatory News:
Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS; Nasdaq:
CLLS), a biopharmaceutical company focused on developing
immunotherapies based on gene edited CAR T-cells (UCART), today
announced five new leading experts will join the Company’s Clinical
Advisory Board (CAB) in 2017 from the fields of hematologic
malignancies, immunotherapy, immunology, stem cell transplantation.
The CAB serves as a strategic resource to Cellectis as the Company
enters the clinical development of allogeneic CAR T
immunotherapies, led by its wholly owned product candidate,
UCART123.
The new board members include Dr Catherine Bollard, Pr Hervé
Dombret, Pr Ola Landgren, Dr Marcela Maus and Pr Dietger
Niederwieser.
“As Cellectis has recently received IND approval from the U.S.
FDA to conduct two Phase 1 clinical trials with UCART123, an
allogeneic, ‘off-the-shelf’ CAR T-cell product candidate for acute
myeloid leukemia (AML) and blastic plasmacytoid dendritic cell
neoplasm (BPDCN), the Company’s Clinical Advisory Board will
continue to play a critical role in establishing new and innovative
immunotherapies for patients all over the world,” said Dr. Loan
Hoang-Sayag, Chief Medical Officer, Cellectis. “As such, we are
pleased these five additional hematology leading experts have now
joined the Board to further guide us in our efforts to transform
cancer treatment through gene editing.”
Professor Catherine Bollard, MBChB, MD, FRACP, FRCPA, is Chief,
Division of Allergy and Immunology and Director of the Program for
Cell Enhancements and Technologies for Immunotherapy at the
Children’s Research Institute, Children's National Health System
and The George Washington University. A distinguished hematologist
and immunotherapist, Dr. Bollard’s research interests focus on
areas that include developing cell and gene therapies for patients
with cancer and underlying immune deficiencies.
Professor Hervé Dombret, MD, is Head of the Leukemia Unit at the
Hôpital Saint Louis, Paris, and Director of Clinical Research in
the Hematology, Immunology and Transplantation Unit, University of
Paris Diderot. He is also Director of the University Hematology
Research Center in Hôpital Saint-Louis and has a PhD in
Oncogenesis. His main fields of interest include clinical and
translational research in acute myeloid leukemia, acute
lymphoblastic leukemia, myelodysplastic syndromes and chronic
myeloid leukemia.
Professor Ola Landgren, MD, is Chief of the Myeloma Service at
Memorial Sloan Kettering Cancer Center New York and Professor of
Medicine at Weill Cornell Medical College. He is a board-certified
hematologist-oncologist whose research focuses on the development
of novel treatment strategies and advanced disease monitoring. He
has a strong interest in the development of early-treatment
clinical trials, targeting high-risk smoldering myeloma. He
develops new strategies (including cell-based, molecular-based and
imaging-based) and implements advanced MRD testing in clinical
trials at MSK.
Doctor Marcela V. Maus, MD, PhD, is Director of Cellular
Immunotherapy at the Massachusetts General Hospital in Boston and
Assistant Professor at Harvard Medical School. She is a
board-certified hematologist-oncologist with extensive research
experience in all aspects of pre-clinical and clinical design and
use of cell therapies and gene-modified T-cells for cancer. Dr Maus
completed undergraduate studies at MIT and her MD and PhD at Penn.
As a graduate student, she worked with Dr. Carl June on the biology
of human T cell activation. She completed residency training in
internal medicine at the University of Pennsylvania Health System,
and completed fellowship training in Hematology and Medical
Oncology at Memorial Sloan Kettering Cancer Center. Her research
focuses on the pre-clinical development and clinical translation of
engineered T cell therapies.
Professor Dietger Niederwieser, MD, is Professor of Medicine,
Head of the Division of Hematology and Medical Oncology at
University of Leipzig and University Hospital. His therapeutic
areas of expertise include Clinical Immunology, Hematology and
Oncology, and his research is focused on stem cell transplantation,
cell therapies and gene therapies. He has extensive experience in
health economics, outcomes research, clinical development of
innovative drugs and clinical studies.
About Cellectis
Cellectis is a biopharmaceutical company focused on developing
immunotherapies based on gene-edited CAR T-cells (UCART). The
company’s mission is to develop a new generation of cancer
therapies based on engineered T-cells. Cellectis capitalizes on its
17 years of expertise in genome engineering - based on its flagship
TALEN® products and meganucleases as well as its pioneering
electroporation PulseAgile technology - to create a new generation
of immunotherapies. CAR technologies are designed to target surface
antigens expressed on cells.
Using its life-science-focused, pioneering genome-engineering
technologies, Cellectis’ goal is to create innovative products in
multiple fields and with various target markets. Cellectis is
listed on the Nasdaq market (ticker: CLLS) and on the NYSE
Alternext market (ticker: ALCLS). To find out more about us, visit
our website: www.cellectis.com
Talking about gene editing? We do it. TALEN® is a registered
trademark owned by the Cellectis Group.
Disclaimer
This press release contains “forward-looking” statements that
are based on our management’s current expectations and assumptions
and on information currently available to management.
Forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause our actual results,
performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by
the forward-looking statements. The risks and uncertainties
include, but are not limited to, the risk that the preliminary
results from our product candidates will not continue or be
repeated, the risk of not obtaining regulatory approval to commence
clinical trials on the UCART product candidates, the risk that any
one or more of our product candidates will not be successfully
developed and commercialized. Further information on the risks
factors that may affect company business and financial performance,
is included in filings Cellectis makes with the Security Exchange
Commission from time to time and its financial reports. Except as
required by law, we assume no obligation to update these
forward-looking statements publicly, or to update the reasons
actual results could differ materially from those anticipated in
the forward-looking statements, even if new information becomes
available in the future.
# # #
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170307006424/en/
For further information, please contact:Media
contacts:CellectisJennifer Moore, 917-580-1088VP of
Communicationsmedia@cellectis.comorKCSA Strategic
CommunicationsCaitlin Kasunich,
212-896-1241ckasunich@kcsa.comorIR contact:CellectisSimon
Harnest, 646-385-9008VP of Corporate Strategy and
Financesimon.harnest@cellectis.com
Cellectis (NASDAQ:CLLS)
Historical Stock Chart
From Apr 2024 to May 2024
Cellectis (NASDAQ:CLLS)
Historical Stock Chart
From May 2023 to May 2024